ZYNLONTA

This brand name is authorized in United States. It is also authorized in Austria, Croatia, Estonia, Ireland, Italy, Lithuania, Romania, UK.

Active ingredients

The drug ZYNLONTA contains one active pharmaceutical ingredient (API):

1	Loncastuximab tesirine UNII 7K5O7P6QIU - LONCASTUXIMAB TESIRINE
	Loncastuximab tesirine is an antibody-drug conjugate (ADC) targeting CD19. Upon binding to CD19, loncastuximab tesirine is internalised followed by release of SG3199 via proteolytic cleavage. The released SG3199 binds to the DNA minor groove and forms highly cytotoxic DNA interstrand crosslinks, subsequently inducing cell death.
	Read more about Loncastuximab tesirine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ZYNLONTA Powder for solution for infusion	MPI, EU: SmPC	European Medicines Agency (EU)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01FX22		L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01F Monoclonal antibodies and antibody drug conjugates → L01FX Other monoclonal antibodies
Discover more medicines within L01FX22

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
EE	Ravimiamet	3039139
IT	Agenzia del Farmaco	050484017
LT	Valstybinė vaistų kontrolės tarnyba	1097040
RO	Agenția Națională a Medicamentului și a Dispozitivelor Medicale	W69620001
US	FDA, National Drug Code	79952-110